AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32246686 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries-free (CF) group
Number of subjects: 120
Study 32246686 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood caries (ECC) group
Number of subjects: 120
Study 32246686 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe early childhood caries (S-ECC) group
Number of subjects: 120
Study 34506241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg insert
Number of subjects: 20
Study 34506241 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% taper
Number of subjects: 20
Study 35616272 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DRSP plus Orlistat
Number of subjects: 66
Study 35616272 — intervention group
Group type: COMPARATOR
Intervention: EE/DRSP alone
Number of subjects: 66
Study 35001412 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 100-400 mg QD
Number of subjects: 40
Study 35001412 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 600 mg QD
Number of subjects: 40
Study 35001412 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg BID
Number of subjects: 40
Study 35001412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35642031 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI)
Number of subjects: 340
Study 32053813 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group (26 patients)
Number of subjects: 49
Study 32053813 — intervention group
Group type: COMPARATOR
Intervention: Normal group (23 subjects)
Number of subjects: 49
Study 35481934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibutyl phthalate (DBP) exposure for 3 hours
Number of subjects: 16
Study 35481934 — intervention group
Group type: COMPARATOR
Intervention: Control air exposure for 3 hours
Number of subjects: 16
Study 33951173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic pack (HP) application
Number of subjects: 25
Study 33951173 — intervention group
Group type: COMPARATOR
Intervention: No hemostatic measures (Control)
Number of subjects: 25
Study 34387216 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking with morphine (0.05‐mg/kg)
Number of subjects: 60
Study 34387216 — intervention group
Group type: COMPARATOR
Intervention: Standard care with morphine (0.05‐mg/kg)
Number of subjects: 60
Study 34862875 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection
Number of subjects: 100
Study 34862875 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 100
Study 33991066 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (TP)
Number of subjects: 34
Study 32321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (persistent dysfunction)
Number of subjects: 29133
Study 32321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (escalating dysfunction)
Number of subjects: 29133
Study 32321881 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no dysfunction)
Number of subjects: 29133
Study 35438450 — intervention group
Group type: EXPERIMENTAL
Intervention: Late booster
Number of subjects: 80
Study 35438450 — intervention group
Group type: EXPERIMENTAL
Intervention: Early booster
Number of subjects: 80
Study 35438450 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 32662540 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0
Study 32662540 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 35225519 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% nepafenac eye drops once daily for 4 weeks
Number of subjects: 2
Study 35225519 — intervention group
Group type: COMPARATOR
Intervention: 0.1% nepafenac eye drops three times/day for 4 weeks
Number of subjects: 2
Study 32585278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine 10% solution (MOB-015)
Number of subjects: 0
Study 32585278 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 32025254 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 8 sessions of 60 minutes each
Number of subjects: 30
Study 32025254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 36198385 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bacillus clausii UBBC‐07
Number of subjects: 0
Study 36198385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Number of subjects: 153
Study 35993161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A (medium exposure)
Number of subjects: 153
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A (high exposure)
Number of subjects: 153
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, low exposure)
Number of subjects: 153
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, medium exposure)
Number of subjects: 153
Study 35993161 — intervention group
Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, high exposure)
Number of subjects: 153
Study 35993161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NAFLD patients)
Number of subjects: 153
Study 33963420 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 322
Study 33963420 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study 32933950 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based insulin titration algorithm
Number of subjects: 575
Study 32933950 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based insulin titration algorithm
Number of subjects: 575
Study 34238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 50
Study 34238679 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 50
Study 33151971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention (low glycaemic index diet plus physical activity)
Number of subjects: 557
Study 33151971 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 557
Study 37353151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based just-in-time training (JITT, short video and simulation)
Number of subjects: 65
Study 37353151 — intervention group
Group type: COMPARATOR
Intervention: Video training (5-minute video)
Number of subjects: 65
Study 33580103 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (10 mg iron, 10 mg zinc, 400 µg vitamin A)
Number of subjects: 347
Study 33580103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 32199882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (anti-IL-12/IL-23 blockade) as induction and maintenance therapy
Number of subjects: 244
Study 32199882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 37602984 — intervention group
Group type: EXPERIMENTAL
Intervention: AHME intervention (social health insurance, social franchising, SafeCare quality-of-care certification programme, business support)
Number of subjects: 8241
Study 37602984 — intervention group
Group type: EXPERIMENTAL
Intervention: AHME intervention
Number of subjects: 8241
Study 37602984 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) experiment
Number of subjects: 8241
Study 33581684 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE4D
Number of subjects: 12
Study 33581684 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study 32956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral strength training (UL; n = 7)
Number of subjects: 15
Study 32956262 — intervention group
Group type: COMPARATOR
Intervention: Bilateral strength training (BL; n = 8)
Number of subjects: 15
Study 32956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 15
Study 32956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral eyes open and bilateral stance tasks
Number of subjects: 15
Study 33880753 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication and parental depressive symptomatology as mediators
Number of subjects: 456
Study 34555068 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT+ET
Number of subjects: 32
Study 34555068 — intervention group
Group type: COMPARATOR
Intervention: ET
Number of subjects: 32
Study 32854756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hwangryunhaedok-tang (HHT)
Number of subjects: 30
Study 32854756 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 30
Study 35914215 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching (N=188)
Number of subjects: 375
Study 35914215 — intervention group
Group type: COMPARATOR
Intervention: Wait-list usual care (n=187)
Number of subjects: 375
Study 34023556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based education
Number of subjects: 160
Study 34023556 — intervention group
Group type: COMPARATOR
Intervention: Booklet-based education
Number of subjects: 160
Study 35385209 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg of anthocyanins (bilberry trihydroxy‐type)
Number of subjects: 52
Study 35385209 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg of anthocyanins (black rice dihydroxy‐type)
Number of subjects: 52
Study 35385209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 34131749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based classifier model using 21 imaging and clinical features
Number of subjects: 266
Study 34131749 — intervention group
Group type: COMPARATOR
Intervention: Human experts using imaging and clinical features
Number of subjects: 266
Study 34131749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based classifier
Number of subjects: 266
Study 34131749 — intervention group
Group type: COMPARATOR
Intervention: Expert humans
Number of subjects: 266
Study 32460997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-day Methotrexate (MTX)
Number of subjects: 57
Study 32460997 — intervention group
Group type: COMPARATOR
Intervention: Pulse Actinomycin-D (ACT-D)
Number of subjects: 57
Study 35238767 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) - 6 applications in 14 days at -130°C for 3 min
Number of subjects: 56
Study 35238767 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 56
Study 35238767 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 56
Study 35710926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) on days 0, 3, 7, 14, and every 2 weeks thereafter (Group A)
Number of subjects: 20
Study 35710926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) every 3 weeks (Group B)
Number of subjects: 20
Study 35710926 — intervention group
Group type: COMPARATOR
Intervention: Control sides (not receiving LLLT)
Number of subjects: 20
Study 35864005 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motivational messages sent via SMS for 21 days
Number of subjects: 60
Study 35864005 — intervention group
Group type: COMPARATOR
Intervention: No motivational messages
Number of subjects: 60
Study 33470654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally controlled pressure support (PSN)
Number of subjects: 24
Study 33470654 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure support ventilation (PSP)
Number of subjects: 24
Study 32570152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 30
Study 32570152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 30
Study 32570152 — intervention group
Group type: COMPARATOR
Intervention: Comparison between labetalol and nifedipine
Number of subjects: 30
Study 35157622 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed collaborative care (TICC)
Number of subjects: 42
Study 35157622 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 42
Study 34054116 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation and deep breathing exercises
Number of subjects: 169
Study 32432339 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 100 mg/d
Number of subjects: 1160
Study 32432339 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 200 mg/d
Number of subjects: 1160
Study 32432339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 35698087 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 2486
Study 35698087 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard treatment
Number of subjects: 2486
Study 33211380 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally processed parsley samples
Number of subjects: 100
Study 35997125 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 vaccine
Number of subjects: 0
Study 35997125 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 35997125 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study 33675838 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 112
Study 33675838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 35140804 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise training program
Number of subjects: 110
Study 35140804 — intervention group
Group type: COMPARATOR
Intervention: Diabetic control group (no intervention)
Number of subjects: 110
Study 35071591 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron proteinsuccinylate oral solution combined with vitamin A and D drops
Number of subjects: 124
Study 35071591 — intervention group
Group type: COMPARATOR
Intervention: Iron proteinsuccinylate oral solution (1.5 mL/kg)
Number of subjects: 124
Study 32978546 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 414
Study 32978546 — intervention group
Group type: COMPARATOR
Intervention: Conventional health education
Number of subjects: 414
Study 33688827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report screening for sleep apnea
Number of subjects: 420
Study 33688827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report screening for insomnia disorder
Number of subjects: 420
Study 33688827 — intervention group
Group type: COMPARATOR
Intervention: Medical record diagnosis of insomnia
Number of subjects: 420
Study 33688827 — intervention group
Group type: COMPARATOR
Intervention: Medical record diagnosis of sleep apnea
Number of subjects: 420
Study 33688827 — intervention group
Group type: COMPARATOR
Intervention: Medical record diagnosis of both conditions
Number of subjects: 420
Study 33688827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall screening for sleep disorders
Number of subjects: 420
Study 35474389 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal SNP rs12785878 (DHCR7)
Number of subjects: 0
Study 35474389 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring SNP rs2282679 (GC)
Number of subjects: 0
Study 35474389 — intervention group
Group type: COMPARATOR
Intervention: Maternal SNP rs1074657
Number of subjects: 0
Study 35474389 — intervention group
Group type: COMPARATOR
Intervention: Maternal SNP rs613897
Number of subjects: 0
Study 35474389 — intervention group
Group type: COMPARATOR
Intervention: Offspring SNP rs1074657
Number of subjects: 0
Study 35474389 — intervention group
Group type: COMPARATOR
Intervention: Offspring SNP rs613897
Number of subjects: 0
Study 34301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walking distance
Number of subjects: 909
Study 34301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 909
Study 34301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic component of physical performance
Number of subjects: 909
Study 34301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Other physical performance components
Number of subjects: 909
Study 33345961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal aerobic exercise (150 minutes of supervised, moderate-intensity aerobic exercise per week)
Number of subjects: 133
Study 33345961 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising group (150 minutes per week of light stretching and relaxation breathing techniques)
Number of subjects: 133
Study 33928372 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive aid (CA) used during simulations
Number of subjects: 34
Study 33928372 — intervention group
Group type: COMPARATOR
Intervention: No digital cognitive aid (CA) used during simulations
Number of subjects: 34
Study 33830181 — intervention group
Group type: COMPARATOR
Intervention: Polygenic risk score derived from HM vs emmetropia GWAS
Number of subjects: 51841
Study 33830181 — intervention group
Group type: COMPARATOR
Intervention: Polygenic risk score derived from LM vs emmetropia GWAS
Number of subjects: 51841
Study 33830181 — intervention group
Group type: COMPARATOR
Intervention: Polygenic risk score derived from hyperopia vs emmetropia GWAS
Number of subjects: 51841
Study 33830181 — intervention group
Group type: COMPARATOR
Intervention: Polygenic risk score derived from LM vs hyperopia GWAS
Number of subjects: 51841
Study 36170042 — intervention group
Group type: EXPERIMENTAL
Intervention: Playful situational game (PSG) intervention
Number of subjects: 116
Study 36170042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PSG)
Number of subjects: 116
Study 36160428 — intervention group
Group type: EXPERIMENTAL
Intervention: Active insula deep rTMS (10 Hz)
Number of subjects: 50
Study 36160428 — intervention group
Group type: COMPARATOR
Intervention: Sham insula deep rTMS
Number of subjects: 50
Study 34775240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg two times daily + Mebeverine 135 mg three times daily
Number of subjects: 50
Study 34775240 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily
Number of subjects: 50
Study 34149014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy for obstructive sleep apnoea (1-2 months duration)
Number of subjects: 152
Study 34149014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy for obstructive sleep apnoea
Number of subjects: 152
Study 35780813 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 convalescent plasma (n = 487)
Number of subjects: 974
Study 35780813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 473)
Number of subjects: 974
Study 35780813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 465)
Number of subjects: 974
Study 33827837 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT plus treatment as usual (TAU)
Number of subjects: 238
Study 33827837 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 238
Study 36495509 — intervention group
Group type: EXPERIMENTAL
Intervention: High NT-proBNP group
Number of subjects: 100
Study 36495509 — intervention group
Group type: COMPARATOR
Intervention: Low NT-proBNP group
Number of subjects: 100
Study 36495509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ventricular hypertrophy
Number of subjects: 100
Study 36495509 — intervention group
Group type: COMPARATOR
Intervention: Patients without left ventricular hypertrophy
Number of subjects: 100
Study 34373019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation (CP) method
Number of subjects: 143
Study 34373019 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous pocket (SP) method
Number of subjects: 143
Study 34373019 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of participants in post-operative infection group
Number of subjects: 143
Study 32803895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind over Matter (MOM) workshop
Number of subjects: 6
Study 34467402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 59
Study 34467402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33317922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in exon 4 or 7 of TP53
Number of subjects: 195
Study 33317922 — intervention group
Group type: EXPERIMENTAL
Intervention: Other TP53 mutations
Number of subjects: 195
Study 33317922 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type TP53
Number of subjects: 195
Study 36008838 — intervention group
Group type: COMPARATOR
Intervention: sarilumab + methotrexate (MOBILITY)
Number of subjects: 2112
Study 36008838 — intervention group
Group type: COMPARATOR
Intervention: sarilumab + conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (TARGET)
Number of subjects: 2112
Study 36008838 — intervention group
Group type: COMPARATOR
Intervention: sarilumab (MONARCH)
Number of subjects: 2112
Study 36008838 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (MONARCH)
Number of subjects: 2112
Study 36008838 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab (both combination and monotherapy)
Number of subjects: 2112
Study 34469763 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3625
Study 34469763 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 3625
Study 32818264 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA alone
Number of subjects: 37
Study 32818264 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA combined with AZI
Number of subjects: 37
Study 32818264 — intervention group
Group type: COMPARATOR
Intervention: AZI alone
Number of subjects: 37
Study 35501156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg haloperidol
Number of subjects: 33
Study 35501156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 34860673 — intervention group
Group type: EXPERIMENTAL
Intervention: app-delivered Mindfulness Training (MT)
Number of subjects: 65
Study 34860673 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (control)
Number of subjects: 65